Literature DB >> 16284605

Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy.

N Demircan1, B G Safran, M Soylu, A A Ozcan, S Sizmaz.   

Abstract

We measured interleukin-1 beta (IL-1beta) and tumour necrosis factor-alpha (TNF-alpha) in the vitreous humour and serum of patients with proliferative diabetic retinopathy (PDR), in order to determine the role of these cytokines in the pathogenesis of the disease. Vitreous and serum samples were collected from 21 patients with PDR who were undergoing pars plana vitrectomy. Control vitreous samples were obtained from cadavers and control serum samples from healthy subjects. The cytokines were measured by enzyme-linked immunosorbent assay. Vitreous IL-1beta and TNF-alpha concentrations in patients with PDR exceeded those of controls (P<0.05), as did serum IL-1beta and TNF-alpha. We suggest that increased vitreous IL-1beta and TNF-alpha levels may play a significant role in the pathogenesis of PDR, which features abnormal cell proliferation and neovascularisation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16284605     DOI: 10.1038/sj.eye.6702138

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  162 in total

1.  The Renin-Angiotensin-Aldosterone System (RAAS) Is One of the Effectors by Which Vascular Endothelial Growth Factor (VEGF)/Anti-VEGF Controls the Endothelial Cell Barrier.

Authors:  Yueru Li; Zhonghao Yan; Komal Chaudhry; Andrius Kazlauskas
Journal:  Am J Pathol       Date:  2020-06-23       Impact factor: 4.307

2.  Novel atypical PKC inhibitors prevent vascular endothelial growth factor-induced blood-retinal barrier dysfunction.

Authors:  Paul M Titchenell; Cheng-Mao Lin; Jason M Keil; Jeffrey M Sundstrom; Charles D Smith; David A Antonetti
Journal:  Biochem J       Date:  2012-09-15       Impact factor: 3.857

3.  Purinergic regulation of high-glucose-induced caspase-1 activation in the rat retinal Müller cell line rMC-1.

Authors:  Katherine E Trueblood; Susanne Mohr; George R Dubyak
Journal:  Am J Physiol Cell Physiol       Date:  2011-08-10       Impact factor: 4.249

4.  Opioid receptor activation: suppression of ischemia/reperfusion-induced production of TNF-α in the retina.

Authors:  Shahid Husain; Gregory I Liou; Craig E Crosson
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-04-20       Impact factor: 4.799

Review 5.  Immunological mechanisms in the pathogenesis of diabetic retinopathy.

Authors:  Anthony P Adamis; Adrienne J Berman
Journal:  Semin Immunopathol       Date:  2008-03-14       Impact factor: 9.623

Review 6.  Mediators of ocular angiogenesis.

Authors:  Yureeda Qazi; Surekha Maddula; Balamurali K Ambati
Journal:  J Genet       Date:  2009-12       Impact factor: 1.166

Review 7.  ω-3 and ω-6 long-chain PUFAs and their enzymatic metabolites in neovascular eye diseases.

Authors:  Yan Gong; Zhongjie Fu; Raffael Liegl; Jing Chen; Ann Hellström; Lois Eh Smith
Journal:  Am J Clin Nutr       Date:  2017-05-17       Impact factor: 7.045

Review 8.  Müller cells and diabetic retinopathy.

Authors:  Brandon A Coughlin; Derrick J Feenstra; Susanne Mohr
Journal:  Vision Res       Date:  2017-09-05       Impact factor: 1.886

9.  Proteolytic cleavage of vascular adhesion protein-1 induced by vascular endothelial growth factor in retinal capillary endothelial cells.

Authors:  Shiho Yoshida; Miyuki Murata; Kousuke Noda; Takashi Matsuda; Michiyuki Saito; Wataru Saito; Atsuhiro Kanda; Susumu Ishida
Journal:  Jpn J Ophthalmol       Date:  2018-02-01       Impact factor: 2.447

10.  Alterations in the intraocular cytokine milieu after intravitreal bevacizumab.

Authors:  Farzin Forooghian; Peter J Kertes; Kenneth T Eng; Elvira Agrón; Emily Y Chew
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-12-10       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.